早发性帕金森病大鼠模型中甲杓肌基因表达研究
本研究对8月龄雄性Pink1-/-大鼠与野生型对照的甲杓肌进行RNA测序,识别出134个差异表达基因,富集于帕金森病、Parkin-泛素蛋白酶体降解、MAPK信号及炎症TNF-α/NF-κB等通路,提示喉肌外周功能障碍机制及实验生物标志物潜力。
要点
- Pink1-/-大鼠甲杓肌存在134个差异表达基因(P<.05)。
- 差异基因富集于帕金森病、Parkin-泛素蛋白酶体、MAPK及炎症通路。
- 结果提示喉肌基因改变可能参与帕金森病发声障碍。
核心结论
- 甲杓肌差异表达基因及通路可能有助于评估喉肌外周功能障碍机制,并有望作为治疗开发的实验生物标志物。
研究设计与样本
- 动物实验含对照,比较8月龄雄性Pink1-/-大鼠与野生型对照的甲杓肌基因表达。
- 采用高通量RNA测序,并用加权基因共表达网络分析构建共表达模块。
- 使用ENRICHR工具将基因集与现有人类基因数据库比较。
主要发现
- 识别出134个注释的差异表达基因(P<.05截断值)。
- 富集于帕金森病通路(Casp7、Pink1)。
- 富集于Parkin-泛素蛋白酶体降解通路(Psmd12、Psmd7)。
- 富集于MAPK信号通路(Casp7、Ppm1b、Ppp3r1)。
- 富集于炎症TNF-α、NF-κB信号通路(Casp7、Psmd12、Psmd7、Cdc34、Bcl7a、Peg3)。
临床怎么用
- 为帕金森病发声障碍的喉肌外周机制研究提供候选基因与通路。
- 提示上述基因或通路可作为治疗开发的实验生物标志物进一步验证。
局限性
- 证据级别为NA,仅基于8月龄雄性Pink1-/-大鼠模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Voice disorders in Parkinson's disease (PD) are early-onset, manifest in the preclinical stages of the disease, and negatively impact quality of life. The complete loss of function in the PTEN-induced kinase 1 gene (Pink1) causes a genetic form of early-onset, autosomal recessive PD. Modeled after the human inherited mutation, the Pink1-/- rat demonstrates significant cranial sensorimotor dysfunction including declines in ultrasonic vocalizations. However, the underlying genetics of the vocal fold thyroarytenoid (TA) muscle that may contribute to vocal deficits has not been studied. The aim of this study was to identify differentially expressed genes in the TA muscle of 8-month-old male Pink1-/- rats compared to wildtype controls. STUDY DESIGN: Animal experiment with control. METHODS: High throughput RNA sequencing was used to examine TA muscle gene expression in adult male Pink1-/- rats and wildtype controls. Weighted Gene Co-expression Network Analysis was used to construct co-expression modules to identify biological networks, including where Pink1 was a central node. The ENRICHR tool was used to compare this gene set to existing human gene databases. RESULTS: We identified 134 annotated differentially expressed genes (P < .05 cutoff) and observed enrichment in the following biological pathways: Parkinson's disease (Casp7, Pink1); Parkin-Ubiquitin proteasome degradation (Psmd12, Psmd7); MAPK signaling (Casp7, Ppm1b, Ppp3r1); and inflammatory TNF-α, Nf-κB Signaling (Casp7, Psmd12, Psmd7, Cdc34, Bcl7a, Peg3). CONCLUSIONS: Genes and pathways identified here may be useful for evaluating the specific mechanisms of peripheral dysfunction including within the laryngeal muscle and have potential to be used as experimental biomarkers for treatment development. LEVEL OF EVIDENCE: NA Laryngoscope, 131:E2874-E2879, 2021.
引用
- Lechner SA, Kletzien H, Gammie SC, et al. Thyroarytenoid Muscle Gene Expression in a Rat Model of Early-Onset Parkinson's Disease. Laryngoscope. 2021. PMID: 34057223. doi:10.1002/lary.29661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。